Study: Vaccine Cervarix may generate higher response than Gardasil
MALMO, Sweden Data from a comparative trial of two vaccines for human papillomavirus indicate that GlaxoSmithKline’s Cervarix may generate a higher immune response than Merck & Co.’s Gardasil.
The study, presented at the International Papillomavirus Conference in Malmo, Sweden, examined two measures of immune response, neutralizing antibodies and memory B cells, which are believed to be important in protecting women from HPV infection. The study found that among women aged 18 to 45, neutralizing antibody levels for Cervarix were more than twice as high as those for Gardasil for HPV type 16 and more than six times higher for HPV type 18. Cervarix also produced almost three times more memory B cells for types 16 and 18.
“The presence of neutralizing antibodies at the location of the infection appears to be an important part of vaccine-induced protection against HPV,” GSK Biologicals chief medical officer and head of global clinical research and development Thomas Breuer said in a statement. “This study offers the first evidence that these two vaccines do not generate the same immune response against HPV types 16 and 18, the two most common cancer-causing virus types.”
OSI Pharmaceuticals EVP to present portfolio at diabetes and obesity conference
MELVILLE, N.Y. OSI Pharmaceuticals, Inc. announced Thursday that Anker Lundemose, M.D., EVP of OSI Pharmaceuticals will present at the Canaccord Adams Conference in New York, N.Y. on Tuesday, May 12, 2009 at 8:40 a.m. (Eastern Time).
Lundemose will provide an overview on the company’s diabetes/obesity product portfolio and business developments.
OSI Pharmaceuticals discover, develop and commercialize high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
FDA grants priority review to Prevnar 13
COLLEGEVILLE, Pa. The Food and Drug Administration has granted priority review to Wyeth Pharmaceuticals’ application for the pneumococcal vaccine Prevnar 13 (diphtheria CRM protein).
The company submitted the application for the vaccine, a 13-valent conjugate vaccine, on March 31.
Wyeth said it is seeking approval for Prevnar 13 for the prevention of invasive pneumococcal disease and otitis media caused by the 13 serotypes in the vaccine in children ages 2 months to 5 years. Prevnar 13 includes six serotypes in addition to the seven in the earlier version of Prevnar.
“Since its launch in 2000, our seven-valent pneumococcal vaccine, Prevnar, has significantly reduced the incidence of pneumococcal disease among infants and young children in the United States,” Wyeth Pharmaceuticals EVP vaccine research and development Emilio Emini said. “Recently, however, disease due to pneumococcal serotypes not found in Prevnar, particularly serotype 19A, have increased in prevalence in many regions of the world and are a significant public health concern.”